Predictive and Impact of Pain After 6 Months of Radiotherapy, in Head and Neck Cancer

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Caen

About this trial

Head and neck cancers are a source of complications and after-effects related to the disease and treatment. These cancers and their treatment alter the quality of life of patients and generate pain with physical and psychological components. Chronic pain affects 36% of patients at 6 months and 30% after this period. These pains are responsible for the consumption of level II and III analgesics in 53% of these patients. At the same time, after the end of treatment, nearly a quarter of patients continued to smoke and half still consumed alcohol at least twice a week.

The hypothesis of this research is to investigate the correlation between pain and the continuation of addictions, the occurrence of depressive states, asthenia and the alteration of the patients' global quality of life.

The investigators propose a two-center prospective cohort study to evaluate this hypothesis at 6 months after radiotherapy treatment.

This study is planned to include 120 patients with a first head and neck cancer whit radiotherapy as part of their treatment sequence. The expected duration of inclusion is 18 months.

The identification of factors affecting survival, quality of life and patient compliance is essential to determine appropriate management, particularly by creating appropriate therapeutic education programs.

Eligibility criteria

Qualifiers

Patients with a first Head and neck cancer whose therapeutic sequence involves radiotherapy

Patient over 18 years of age

Having given written consent

patient not previously treated with radiotherapy

Disqualifiers

Non-consenting patient

History of malignancy, other than treated and cured basal cell or cervical cancer

Patient who has had a salvage surgery other than lymph node removal

Patient with evidence of recurrence or other progressive neoplasia at the time of examination

Trial design

Treatments tested in this trial

  • Questionnaire

Treatment groups

120 Participants
are divided into 1 treatment group

Sponsors and collaborators

University Hospital, Caen

Lead sponsor

Centre Francois Baclesse

Collaborator